Nano- and Microcap Stocks

  • Nano- and Microcap Stocks

    nana wrote:

    Quote
    APCX

    will bis 0.002 '?????


    definitiv 2. mit einbisschen glück geht die App Tech Aktie bis auf 4.


    joah.. kann man downloaden im; App Store - Downloads bei iTunes, für 1.20$ glaube ich.


    "See Jesus App".


    aiight

    bubble gum?

  • Nano- and Microcap Stocks

    Vagnum wrote:


    bin heute wieder bei 0.0014 rein


    mal sehen

  • Nano- and Microcap Stocks

    nana wrote:

    Quote

    Vagnum wrote:


    bin heute wieder bei 0.0014 rein


    mal sehen


    heute? :D


    dann hast du 0.0015 bezahlt oder? :D gratuliere. ;).

    super trade. 8)

    bubble gum?

  • Nano- and Microcap Stocks

    Vagnum wrote:

    Quote

    nana wrote:


    heute? :D


    dann hast du 0.0015 bezahlt oder? :D gratuliere. ;).

    super trade. 8)


    nein habe 0.0014 bezahlt war selber überrascht

  • Re: APCX 1.60$

    Vagnum wrote:

    Quote
    in @ APCX 16, small. 300$ trade.


    lohnt sich. bin dazumal auch nur mit 300 rein. waren 2 tage später 500. lohnt sich total das kleine viech.


    werde mir nachher nochmals eine posi zu 300 nehmen.

    Handelnder Holländer

  • Re: APCX 1.60$

    WARSICS wrote:

    Quote

    Vagnum wrote:


    lohnt sich. bin dazumal auch nur mit 300 rein. waren 2 tage später 500. lohnt sich total das kleine viech.


    werde mir nachher nochmals eine posi zu 300 nehmen.


    die 2 haben wir jetzt und..............

  • Nano- and Microcap Stocks

    leider immernoch nichts wieder bekommen... :shock:


    19 ist mir zu viel. wobei, in 2 wochen sagen wir evtl. 30 ist mir zu viel.... hmpf :cry:

    Handelnder Holländer

  • Re: APCX 1.60$

    nana wrote:

    Quote

    WARSICS wrote:


    die 2 haben wir jetzt und..............




    nöö sind erst 19$. :roll: morgen 20 auf dem BID.

    ich hab 300 $ drin mir ists egal...

    bubble gum?

  • Nano- and Microcap Stocks

    WARSICS wrote:

    Quote
    leider immernoch nichts wieder bekommen... :shock:

    19 ist mir zu viel. wobei, in 2 wochen sagen wir evtl. 30 ist mir zu viel.... hmpf :cry:


    warum den nichts

  • APCX

    8:06AM



    AppTech Announces That It Is in the Process of Obtaining a Software License for Smartphone Apps


    AppTech Corp (Pink Sheets: APCX) is pleased to announce that it is in the process of obtaining a license for software that will allow for multi platform app development and will enable AppTech to create a portal for app developers and individuals who have an interest in developing "app ideas." The portal will offer app development software for a nominal monthly fee and will allow developers and/or app idea people to create apps on multi operating system smart phones. The portal will lend itself to advertising of general app services and will also offer a joint venture business model for individuals with app ideas that AppTech believes have applications that will generate revenue for both parties. AppTech will develop the app and share revenue at pre-determined percentages. In addition, AppTech intends to develop a menu of smart phone apps that up to now have been in "incubator" mode. Eric Ottens, AppTech's CEO commented: "Nearly every day we receive ideas for developing apps. Some ideas are silly but some ideas have some real merit. We intend to offer the tools for potential app developers to develop, distribute and market their app ideas and give them a chance to make a few bucks. We believe the potential for this market is huge."

  • MRNJ

    8:06AM



    Metatron/i-Mobilize and TravelVideoStore.com Partner to Capture the Mobile Video Travel Market




    Metatron, Inc. (PINKSHEETS: MRNJ) -- TravelVideoStore.com, one of the largest independent distributors of videos, has taken an equity stake in Metatron Inc and extended its licensing agreement of thousands of titles to Metatron's i-Mobilize. This new partnership leverages the vast catalog of titles of TravelVideoStore.com with the technology and reach of Metatron's i-Mobilize in mobile content distribution. Nearly 100 iPhone/iPad apps have already been created by i-Mobilize using the top-selling content provided by TravelVideoStore.com, and hundreds more are expected to be released in the next few months on all major platforms.


    TravelVideoStore.com started in 2003 and features travel videos to destinations around the world offering tourist, excursion, vacation, and travel video guides to more places than any other company. TravelVideoStore.com works with over 700 film producers and has over 6,000 films in its library which generates millions a year in revenue. In 2010 Travel Video Store also won "The Best of Business Award" for their category by the SBCA.


    "We are honored to be working with TravelVideoStore.com and appreciate their investment into the Company, and we look forward to conquering new markets with TravelVideoStore.com." -- CEO Joe Riehl Metatron Inc.

  • Nano- and Microcap Stocks

    b00n wrote:

    Quote
    APCX

    % BUYS liegen soeben vorne


    mhh jetzt nicht mehr, könnt ein sell the uninteressanten news geben...


    market cap 160k.


    wenn man den letzten news glaubt und die verkaufszahlen so schnell vorangehen müsste man eine marketcap von ca. 230-250k erreichen im März.


    mal gucken...

    bubble gum?

  • WATCH IT

    lang erwarteter break out gekommen.. (gestern)


    das war der grund dazu


    Intellect Neurosciences, Inc. Obtains New Patent for Alzheimer's Vaccine From the United States Patent and Trademark Office


    Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that it has received a new patent from the United States Patent and Trademark Office ("USPTO") in relation to the Company's RECALL-VAXTM technology platform. Patents for RECALL-VAXTM have been issued in Europe, Australia, New Zealand and South Africa, and corresponding patent applications are pending in Canada, China, Japan and Israel. RECALL-VAXTM is a method to immunize people to produce highly specific natural antibodies against the beta amyloid ("Aβ") protein before it causes irreversible damage by accumulating in the brains of Alzheimer's patients. The vaccine has the potential to delay onset or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor. The approach can be applied to additional therapeutic targets associated with Alzheimer's and other neurodegenerative conditions. Professor Benjamin Chain, Department of Immunology, UCL School of Life and Medical Sciences, London, UK, is the inventor of RECALL-VAXTM. Professor Chain, brother of Dr. Daniel Chain, Intellect's Chairman and Chief Executive Officer, is a member of the Company's scientific advisory board.


    Dr. Daniel Chain commented: "This new patent from the USPTO is yet another important milestone for the Company and is indicative of the type of ground breaking research we do that is aimed at discovering and developing drugs that can fundamentally transform the way Alzheimer's disease is treated and ultimately prevent the onset of the disease. Intellect has two immunotherapy approaches: The more advanced of the two is the ANTISENILIN® platform, which uses recombinant monoclonal antibodies as highly specific drugs to prevent the accumulation of soluble Aβ in the brains of Alzheimer's patients. The ANTISENILIN® technology underlies products under development by major pharmaceutical companies, such as Ponezumab in Phase 2 and Bapineuzumab in Phase 3 clinical trials, respectively. RECALL-VAXTM pinpoints the same unique molecular signatures at the ends of Aβ to reproduce the same type of specificity that can be obtained using ANTISENILIN® monoclonal antibodies. However, instead of administering antibodies to patients, RECALL-VAXTM involves injecting a small piece of Aβ coupled to an innocuous bacterial protein with the goal of allowing the patient's immune system to generate antibodies that uniquely bind Aβ. A vaccine of this nature, which is analogous to a flu shot, could be viewed as the ultimate quest in Alzheimer's research. We look forward to developing drug candidates based on RECALL-VAXTM technology with the aim of ultimately testing the vaccine in human clinical trials."